Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse-transcriptase polymerase chain reaction
Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse-transcriptase polymerase chain reaction
复制标题
DOI：
10.1002/hep.510290223
复制
发表时间：
1999-02-01
期刊：
影响因子：
13.5
通讯作者：
Hadengue, A
中科院分区：
文献类型：
--
作者：
Negro, F;Krawczynski, K;Hadengue, A
由于现有技术的敏感性和特异性不足，旨在将肝内丙型肝炎病毒(HCV)-RNA水平与解剖-临床特征相关联的研究一直很困难。我们效价strand-specific基因组和负链HCV RNA,半定量的,genotype-independent逆转录酶聚合酶链反应(rt - pcr) 61慢性丙型肝炎患者的肝组织研究结果与血清中HCV RNA水平,HCV基因型,肝内HCV抗原的表达,组织活动(使用单独的分数的小叶和门户/坏死炎性组织活动和门静脉周的纤维化),以及对干扰素（ifn - α）治疗的反应。在59例和57例肝脏标本中分别检测到基因组链和负链HCV RNA。血清中HCV-RNA水平与基因组链相关，但与肝脏中负链HCV-RNA滴度无关。肝内HCV RNA的任何一条链与肝脏中HCV抗原的表达水平或与潜在肝脏疾病的分级/分期之间均未发现相关性。对ifn - α治疗的反应可以通过血清HCV-RNA水平和基因型预测，但不能通过肝内基因组或负链HCV RNA水平预测。这些结果表明，尽管检测负链HCV RNA可以可靠地识别目标器官中复制HCV的存在，但病毒血症的定量测量仍然是评估HCV复制水平的临床有意义的“黄金标准”。
Studies aimed at correlating the intrahepatic hepatitis C virus (HCV)-RNA level and anatomo-clinical features have been difficult because of sensitivity and specificity shortcomings of available techniques. We titered the genomic- and minus-strand HCV RNAs by a strand-specific, semiquantitative, genotype-independent reverse-transcriptase polymerase chain reaction (RT-PCR) in the liver tissue of 61 patients with chronic hepatitis C. Findings were correlated with the levels of HCV RNA in the serum, the HCV genotype, the expression of intrahepatic HCV antigens, the histological activity (using separate scores for the lobular and the portal/periportal necroinflammatory activity and for the fibrosis), and the response to interferon alfa (IFN-alpha) treatment. Genomic- and minus-strand HCV RNA were detected in 59 and 57 liver specimens, respectively. The HCV-RNA level in the serum correlated with the genomic-strand, but not with the minus-strand, HCV-RNA titer in the liver. No correlations were found between either strand of the intrahepatic HCV RNA and the level of expression of HCV antigens in the liver, or with the grading/staging of the underlying liver disease. The response to IFN-alpha treatment could be predicted by the serum HCV-RNA level and genotype, but not by the intrahepatic level of genomic- or minus-strand HCV RNA. These results suggest that, although the detection of the minus-strand HCV RNA reliably identifies the presence of replicating HCV in its target organ, the quantitative measurement of viremia remains the clinically meaningful "golden standard" for assessing the level of HCV replication.